VHX-896
Bipolar I Disorder
Vanda PharmaceuticalsPhase 1Active
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 81/ 100
Competitive context
33 Active assets in the Bipolar I Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lurasidone Massachusetts General Hospital | Phase 4 | BBB |
Cipralex Massachusetts General Hospital | Phase 4 | BBB |
LITHIUM, ELEMENTAL Alzamend Neuro, Inc. | Phase 4 | BBB |
Olanzapine Alkermes, Inc. | Phase 4 | BBB |
Asenapine Organon and Co | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
VHX-896 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →